{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:09:12Z","timestamp":1753891752858,"version":"3.41.2"},"reference-count":93,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T00:00:00Z","timestamp":1591142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.00777","type":"journal-article","created":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T05:36:26Z","timestamp":1591162586000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Cellular Immunotherapy and Locoregional Administration of CAR T-Cells in Malignant Pleural Mesothelioma"],"prefix":"10.3389","volume":"10","author":[{"given":"Robert A.","family":"Belderbos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heleen","family":"Vroman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim G. J. V.","family":"Aerts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,6,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1093\/annonc\/mdv199","article-title":"Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Baas","year":"2015","journal-title":"Ann Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nrc.2017.42","article-title":"Novel insights into mesothelioma biology and implications for therapy","volume":"17","author":"Yap","year":"2017","journal-title":"Nat Rev Cancer."},{"key":"B3","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3322\/caac.21572","article-title":"Mesothelioma: Scientific clues for prevention, diagnosis, and therapy","volume":"69","author":"Carbone","year":"2019","journal-title":"CA Cancer J Clin."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"French cooperative thoracic, bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.2217\/fon-2017-0307","article-title":"A review of bevacizumab in the treatment of malignant pleural mesothelioma","volume":"13","author":"Brosseau","year":"2017","journal-title":"Future Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas Wolchok","year":"2018","journal-title":"Science."},{"key":"B8","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1053\/j.seminoncol.2015.02.001","article-title":"Immune checkpoint blockade in malignant mesothelioma","volume":"42","author":"Calabro","year":"2015","journal-title":"Semin Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S2213-2600(15)00092-2","article-title":"Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study","volume":"3","author":"Calabro","year":"2015","journal-title":"Lancet Respir Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/S2213-2600(18)30420-X","article-title":"Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial","volume":"7","author":"Disselhorst","year":"2019","journal-title":"Lancet Respir Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1001\/jamaoncol.2018.5428","article-title":"Efficacy and safety of avelumab treatment in patients with advanced unresectable mesothelioma: phase 1b results from the JAVELIN Solid Tumor Trial","volume":"5","author":"Hassan","year":"2019","journal-title":"JAMA Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1164\/rccm.201608-1755CI","article-title":"Checkpoint blockade in lung cancer and mesothelioma","volume":"196","author":"Lievense","year":"2017","journal-title":"Am J Respir Crit Care Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"5485","DOI":"10.1158\/1078-0432.CCR-19-0103","article-title":"Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT)","volume":"25","author":"Okada Kijima","year":"2019","journal-title":"Clin Cancer Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/j.jtho.2018.05.038","article-title":"Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma","volume":"13","author":"Quispel-Janssen","year":"2018","journal-title":"J Thorac Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1016\/j.jtho.2018.08.007","article-title":"Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma","volume":"13","author":"Metaxas","year":"2018","journal-title":"J Thorac Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"S338","DOI":"10.1016\/j.jtho.2018.08.276","article-title":"OA08.02 DREAM - A Phase 2 trial of durvalumab with first line chemotherapy in mesothelioma: final result","volume":"13","author":"Nowak Kok","year":"2018","journal-title":"J Thorac Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1080\/14712598.2019.1606209","article-title":"Immune checkpoint inhibition for the treatment of mesothelioma","volume":"19","author":"Nowak","year":"2019","journal-title":"Expert Opin Biol Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"v851","DOI":"10.1093\/annonc\/mdz394.091","article-title":"A multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM) \u2013 results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial","volume":"30","author":"Popat","year":"2019","journal-title":"Ann Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"French cooperative thoracic, nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel Mazieres","year":"2019","journal-title":"Lancet Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S2213-2600(18)30151-6","article-title":"Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study","volume":"6","author":"Calabro","year":"2018","journal-title":"Lancet Respir Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"TPS8581","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS8581","article-title":"Checkmate 743: A phase 3, randomized, open-label trial of nivolumab (nivo) plus ipilimumab (ipi) vs pemetrexed plus cisplatin or carboplatin as first-line therapy in unresectable pleural mesothelioma","volume":"35","author":"Gerard","year":"2017","journal-title":"J Clin Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1126\/science.1232227","article-title":"Neutralizing tumor-promoting chronic inflammation: a magic bullet?","volume":"339","author":"Coussens","year":"2013","journal-title":"Science."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1158\/0008-5472.CAN-12-3932","article-title":"Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer","volume":"73","author":"Aerts","year":"2013","journal-title":"Cancer Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e1082028","DOI":"10.1080\/2162402X.2015.1082028","article-title":"Human mesothelioma induces defects in dendritic cell numbers and antigen-processing function which predict survival outcomes","volume":"5","author":"Cornwall","year":"2016","journal-title":"Oncoimmunology."},{"key":"B26","first-page":"785","article-title":"How do lymphocytes kill tumor cells?","volume":"2","author":"Graubert","year":"1996","journal-title":"Clin Cancer Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.1158\/1078-0432.CCR-15-0685","article-title":"How do cytotoxic lymphocytes kill cancer cells?","volume":"21","author":"Mart\u00ednez-Lostao","year":"2015","journal-title":"Clin Cancer Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1007\/s00262-018-2158-4","article-title":"Personalized cancer vaccines: adjuvants are important, too","volume":"67","author":"Gouttefangeas","year":"2018","journal-title":"Cancer Immunol Immunother."},{"key":"B29","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1080\/21645515.2015.1071455","article-title":"Safety and tolerability evaluation of the use of Montanide ISA51 as vaccine adjuvant: a systematic review","volume":"12","author":"van Doorn","year":"2016","journal-title":"Hum Vaccin Immunother."},{"key":"B30","doi-asserted-by":"publisher","first-page":"77872","DOI":"10.18632\/oncotarget.20845","article-title":"Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1","volume":"8","author":"Eguchi","year":"2017","journal-title":"Oncotarget."},{"key":"B31","doi-asserted-by":"publisher","first-page":"7483","DOI":"10.1158\/1078-0432.CCR-17-2169","article-title":"A Randomized phase II trial of adjuvant galinpepimut-S, WT-1 analogue peptide vaccine, after multimodality therapy for patients with malignant pleural mesothelioma","volume":"23","author":"Zauderer","year":"2017","journal-title":"Clin Cancer Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1158\/1078-0432.CCR-11-2614","article-title":"Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients","volume":"18","author":"Servais","year":"2012","journal-title":"Clin Cancer Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1097\/01.MP.0000056981.16578.C3","article-title":"Value of mesothelin immunostaining in the diagnosis of mesothelioma","volume":"16","author":"Ordonez","year":"2003","journal-title":"Mod Pathol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"5787","DOI":"10.1158\/1078-0432.CCR-19-0070","article-title":"Live-attenuated, listeria monocytogenes expressing mesothelin (CRS-207) with chemotherapy for treatment of malignant pleural mesothelioma","volume":"25","author":"Hassan","year":"2019","journal-title":"Clin Cancer Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"S156","DOI":"10.1016\/S1556-0864(16)30330-6","article-title":"208O_PR: CRS-207 with chemotherapy (chemo) in malignant pleural mesothelioma (MPM): results from a phase 1b trial","volume":"11","author":"Jahan","year":"2016","journal-title":"J Thorac Oncol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1200\/JCO.2019.37.8_suppl.29","article-title":"A phase II single-arm study of CRS-207 with pembrolizumab (pembro) in previously treated malignant pleural mesothelioma (MPM)","volume":"37","author":"Evan","year":"2019","journal-title":"J Clin Oncol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3389\/fimmu.2019.00008","article-title":"Vaccine strategies to improve anti-cancer cellular immune responses","volume":"10","author":"Vermaelen","year":"2019","journal-title":"Front Immunol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"25961","DOI":"10.4161\/onci.25961","article-title":"Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy","volume":"2","author":"Devaud","year":"2013","journal-title":"Oncoimmunology."},{"key":"B39","doi-asserted-by":"publisher","first-page":"214","DOI":"10.3389\/fonc.2015.00214","article-title":"Remodeling components of the tumor microenvironment to enhance cancer therapy","volume":"5","author":"Gkretsi","year":"2015","journal-title":"Front Oncol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.omto.2019.03.007","article-title":"Enhancing dendritic cell therapy in solid tumors with immunomodulating conventional treatment","volume":"13","author":"Belderbos","year":"2019","journal-title":"Mol Ther Oncolytics."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.3389\/fimmu.2018.02759","article-title":"Combination strategies to optimize efficacy of dendritic cell-based immunotherapy","volume":"9","author":"van Gulijk","year":"2018","journal-title":"Front Immunol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.it.2017.05.006","article-title":"Integrating next-generation dendritic cell vaccines into the current cancer immunotherapy landscape","volume":"38","author":"Garg","year":"2017","journal-title":"Trends Immunol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.1016\/S1470-2045(13)70585-0","article-title":"Clinical use of dendritic cells for cancer therapy","volume":"15","author":"Anguille","year":"2014","journal-title":"Lancet Oncol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/nm1100","article-title":"Cancer immunotherapy: moving beyond current vaccines","volume":"10","author":"Rosenberg","year":"2004","journal-title":"Nat Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1158\/1078-0432.CCR-15-1399","article-title":"Dendritic cell-based immunotherapy: state of the art and beyond","volume":"22","author":"Bol","year":"2016","journal-title":"Clin Cancer Res."},{"key":"B46","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s40425-019-0580-6","article-title":"The clinical application of cancer immunotherapy based on naturally circulating dendritic cells","volume":"7","author":"Bol","year":"2019","journal-title":"J Immunother Cancer."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1200\/JCO.2015.63.4121","article-title":"Phase II study of autologous monocyte-derived mRNA electroporated dendritic cells (TriMixDC-MEL) plus ipilimumab in patients with pretreated advanced melanoma","volume":"34","author":"Wilgenhof","year":"2016","journal-title":"J Clin Oncol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.smim.2008.09.006","article-title":"Antigens for cancer immunotherapy","volume":"20","author":"Neller","year":"2008","journal-title":"Semin Immunol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2217\/imt.09.35","article-title":"Why current peptide-based cancer vaccines fail: lessons from the three Es","volume":"1","author":"Claesson","year":"2009","journal-title":"Immunotherapy"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2567.2007.02587.x","article-title":"Cancer immunoediting from immune surveillance to immune escape","volume":"121","author":"Kim","year":"2007","journal-title":"Immunology."},{"key":"B51","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/978-3-030-16884-1_19","article-title":"Immunotherapy of mesothelioma: vaccines and cell therapy","volume-title":"Mesothelioma: From Research to Clinical Practice","author":"Belderbos","year":"2019"},{"key":"B52","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","article-title":"Cancer immunoediting and resistance to T cell-based immunotherapy","volume":"16","author":"O'Donnell","year":"2019","journal-title":"Nat Rev Clin Oncol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science."},{"key":"B54","doi-asserted-by":"publisher","first-page":"7583","DOI":"10.1200\/jco.2014.32.15_suppl.7583","article-title":"Dendritic cell vaccination in malignant pleural mesothelioma: A phase I\/II study","volume":"32","author":"Berneman","year":"2014","journal-title":"J Clin Oncol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1016\/j.jcyt.2016.03.036","article-title":"Vaccination with Wilms' Tumor Antigen (WT1) mRNA-electroporated dendritic cells as an adjuvant treatment in 60 cancer patients: report of clinical effects and increased survival in acute myeloid leukemia, metastatic breast cancer, glioblastoma and mesothelioma","volume":"18","author":"Berneman","year":"2016","journal-title":"Cytotherapy."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1164\/rccm.201508-1573OC","article-title":"Extended tumor control after dendritic cell vaccination with low-dose cyclophosphamide as adjuvant treatment in patients with malignant pleural mesothelioma","volume":"193","author":"Cornelissen","year":"2016","journal-title":"Am J Respir Critic Care Med."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1164\/rccm.200909-1465OC","article-title":"Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma","volume":"181","author":"Hegmans","year":"2010","journal-title":"Am J Respir Critic Care Med."},{"key":"B58","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s00262-012-1388-0","article-title":"Chemoimmunotherapy: reengineering tumor immunity","volume":"62","author":"Chen","year":"2013","journal-title":"Cancer Immunol Immunother."},{"key":"B59","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.ccell.2015.10.012","article-title":"Immunological effects of conventional chemotherapy and targeted anticancer agents","volume":"28","author":"Galluzzi","year":"2015","journal-title":"Cancer Cell."},{"key":"B60","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s00262-006-0225-8","article-title":"Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients","volume":"56","author":"Ghiringhelli","year":"2007","journal-title":"Cancer Immunol Immunother."},{"key":"B61","doi-asserted-by":"publisher","first-page":"e1474318","DOI":"10.1080\/2162402X.2018.1474318","article-title":"Low-dose cyclophosphamide depletes circulating naive and activated regulatory T cells in malignant pleural mesothelioma patients synergistically treated with dendritic cell-based immunotherapy","volume":"7","author":"Noordam","year":"2018","journal-title":"Oncoimmunology."},{"key":"B62","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1158\/1078-0432.CCR-17-2522","article-title":"Autologous dendritic cells pulsed with allogeneic tumor cell lysate in mesothelioma: from mouse to human","volume":"24","author":"Aerts","year":"2017","journal-title":"Clin Cancer Res."},{"key":"B63","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1158\/1538-7445.AM2019-2249","article-title":"Abstract 2249: checkpoint inhibitor therapy after dendritic cell vaccination elicits tumor response in mesothelioma patients","volume":"79","author":"Cornelissen","year":"2019","journal-title":"Cancer Res."},{"key":"B64","doi-asserted-by":"publisher","first-page":"280","DOI":"10.21037\/tlcr.2019.05.05","article-title":"A multicenter, randomized, phase II\/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma (DENIM) trial","volume":"8","author":"Belderbos","year":"2019","journal-title":"Transl Lung Cancer Res."},{"key":"B65","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1158\/2326-6066.CIR-16-0309","article-title":"Depletion of tumor-associated macrophages with a CSF-1R kinase inhibitor enhances antitumor immunity and survival induced by DC immunotherapy","volume":"5","author":"Dammeijer","year":"2017","journal-title":"Cancer Immunol Res."},{"key":"B66","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.jtho.2019.08.598","volume":"2019","author":"Belderbos","year":"2019","journal-title":"09 Checkpoint Inhibitors Synergize With Dendritic Cell-Therapy in Pre-Clinical Models And Mesothelioma Patients"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","article-title":"Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma","volume":"319","author":"Rosenberg","year":"1988","journal-title":"N Engl J Med."},{"key":"B68","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41416-018-0325-1","article-title":"Teaching an old dog new tricks: next-generation CAR T cells","volume":"120","author":"Tokarew","year":"2019","journal-title":"Br J Cancer."},{"key":"B69","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1126\/science.1129003","article-title":"Cancer regression in patients after transfer of genetically engineered lymphocytes","volume":"314","author":"Morgan","year":"2006","journal-title":"Science."},{"key":"B70","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.1158\/1078-0432.CCR-14-2675","article-title":"The evolution of T-cell therapies for solid malignancies","volume":"21","author":"Fousek","year":"2015","journal-title":"Clin Cancer Res."},{"key":"B71","doi-asserted-by":"publisher","first-page":"16006","DOI":"10.1038\/mto.2016.6","article-title":"Chimeric antigen receptor T-cell therapy for solid tumors","volume":"3","author":"Newick","year":"2016","journal-title":"Mol Ther Oncolytics."},{"key":"B72","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40364-017-0102-y","article-title":"Engineering CAR-T cells","volume":"5","author":"Zhang","year":"2017","journal-title":"Biomark Res."},{"key":"B73","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3389\/fonc.2019.00069","article-title":"Next Generation CAR T Cells for the Immunotherapy of High-Grade Glioma","volume":"9","author":"Petersen","year":"2019","journal-title":"Front Oncol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/hon.2591","article-title":"CAR T-cell therapy: full speed ahead","volume":"37","author":"Sermer","year":"2019","journal-title":"Hematol Oncol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEsJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med."},{"key":"B77","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med."},{"key":"B78","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41419-018-0278-6","article-title":"CAR-T cells: the long and winding road to solid tumors","volume":"9","author":"D'Aloia","year":"2018","journal-title":"Cell Death Dis."},{"key":"B79","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3389\/fimmu.2019.00128","article-title":"CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment","volume":"10","author":"Martinez","year":"2019","journal-title":"Front Immunol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood."},{"key":"B81","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1182\/blood-2011-01-325266","article-title":"Autoimmunity associated with immunotherapy of cancer","volume":"118","author":"Amos","year":"2011","journal-title":"Blood."},{"key":"B82","doi-asserted-by":"publisher","first-page":"v501","DOI":"10.1093\/annonc\/mdz253.052","article-title":"A phase I clinical trial of malignant pleural mesothelioma treated with locally delivered autologous anti-FAP-targeted CAR T-cells","volume":"30","author":"Curioni Britschgi","year":"2019","journal-title":"Ann Oncol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","article-title":"Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies","volume":"2","author":"Beatty","year":"2014","journal-title":"Cancer Immunol Res."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/j.ymthe.2019.07.015","article-title":"Phase I Study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers","volume":"27","author":"Haas","year":"2019","journal-title":"Mol Ther."},{"key":"B85","doi-asserted-by":"publisher","first-page":"CT036","DOI":"10.1158\/1538-7445.AM2019-CT036","article-title":"Abstract CT036: A phase I clinical trial of malignant pleural disease treated with regionally delivered autologous mesothelin-targeted CAR T cells: safety and efficacy","volume":"79","author":"Adusumilli","year":"2019","journal-title":"Cancer Res."},{"key":"B86","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3390\/cancers9090115","article-title":"Chimeric Antigen Receptor (CAR) T cell therapy for Malignant Pleural Mesothelioma (MPM)","volume":"9","author":"Klampatsa Haas","year":"2017","journal-title":"Cancers."},{"key":"B87","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.canlet.2017.02.015","article-title":"Intracavitary 'T4 immunotherapy' of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells","volume":"393","author":"Klampatsa Achkova","year":"2017","journal-title":"Cancer Lett."},{"key":"B88","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.lungcan.2012.03.008","article-title":"Overexpression and potential targeting of the oncofoetal antigen 5T4 in malignant pleural mesothelioma","volume":"77","author":"Al-Taei","year":"2012","journal-title":"Lung Cancer."},{"key":"B89","doi-asserted-by":"publisher","first-page":"4719","DOI":"10.1158\/1078-0432.CCR-11-0351","article-title":"Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor","volume":"17","author":"Moon","year":"2011","journal-title":"Clin Cancer Res."},{"key":"B90","doi-asserted-by":"publisher","first-page":"261ra151","DOI":"10.1126\/scitranslmed.3010162","article-title":"Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity","volume":"6","author":"Adusumilli","year":"2014","journal-title":"Sci Transl Med."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.trsl.2017.04.004","article-title":"CAR T-cell therapy for lung cancer and malignant pleural mesothelioma","volume":"187","author":"Zeltsman","year":"2017","journal-title":"Transl Res."},{"key":"B92","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1172\/JCI83092","article-title":"Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition","volume":"126","author":"Cherkassky","year":"2016","journal-title":"J Clin Invest."},{"key":"B93","article-title":"Intrapleurally administered CAR T-cell immunotherapy plus anti\u2013PD-1 therapy holds promise for mesothelin-expressing solid tumors","volume-title":"ASCO Annual Meeting","author":"Gordon","year":"2019"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00777\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T05:36:30Z","timestamp":1591162590000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00777\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,3]]},"references-count":93,"alternative-id":["10.3389\/fonc.2020.00777"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.00777","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2020,6,3]]},"article-number":"777"}}